心臓病・神経向けIVDの市場規模、シェア、動向分析レポート：製品タイプ別、技術別、最終用途別、地域別、セグメント別予測、2024年～2030年

心臓病・神経向けIVD市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、心臓病・神経向けIVDの世界市場規模は、2024年から2030年にかけて9.44%のCAGRを記録し、2030年までに305億4,000万米ドルに達すると予測されています。

市場成長の主な原動力は、老年人口の増加に伴う心血管障害や神経障害の有病率の増加です。世界心臓連盟が発表した論文によると、2023年、心血管疾患（CVD）は世界の主要な死因であり、2021年に登録された推定死亡者数は2,050万人です。さらに、神経疾患は世界人口の15％が罹患していることが判明しています。

新薬や既存薬とバイオマーカーを組み合わせた革新的な治療法が次々と発表されています。例えば現在、神経疾患の治療には、分子を測定することで脳の健康状態を追跡するバイオマーカーが使用されています。バイオマーカーシグネチャーのような最近のバイオマーカーの進歩は、神経疾患の治療を強化しています。その結果、早期診断、迅速な薬剤開発、非侵襲的検査が可能になりました。さらに、デジタルバイオマーカーは、多くの製薬会社に臨床試験の決定を下すための文脈的で補足的な情報を提供しています。例えば、IXICO Plcは、臨床的にデジタルバイオマーカーを認証し、臨床試験で使用するために、主要なバイオ製薬会社と協力しています。

さらに、ADや軽度外傷性脳損傷などの適応症の診断のためのBBBM検査の開発と導入が市場成長に寄与しています。例えば、2020年3月、NIHの資金提供を受けた研究者は、アルツハイマー病の存在を示すリン酸化タウ181（ptau181）を検出する血液ベースの検査を開発しました。このアプローチは、既存の脳画像検査や髄液検査よりもコストと侵襲性が低いです。同様に、アボット社は2021年1月、脳震盪を含む外傷性脳損傷のための初の迅速血液検査を導入しました。この検査は、外傷性脳損傷後の血液中に含まれる特定のタンパク質を測定するもので、検査結果が陰性の場合、CTスキャンの必要性を除外するために使用できます。

さらに、IVDは、様々な病気の診断やモニタリングのために、様々な臨床分野で重要性を増しています。心血管疾患や神経疾患に対する新しいIVDソリューションの利用可能性の増加は、市場成長を促進すると予想される主要な要因の1つです。例えば、2023年10月、Mindray社は、2つの新規の高感度NT-proBNPおよびトロポニンi（hs-cTnI）心臓バイオマーカーの発売により、心臓バイオマーカーのポートフォリオを拡大すると発表しました。今回の上市により、同社はCVDのより良い診断と管理のための革新的な技術で既存のポートフォリオを強化・多様化することを目指します。さらに、2023年7月、クエスト・ダイアグノスティックスは、アルツハイマー病発症の潜在的なリスクにアクセスするのに役立つ、一般消費者向けの初の検査であるアルツハイマー病AD-Detect検査の提供を発表しました。

心臓病・神経向けIVD市場レポートハイライト

• 試薬・消耗品セグメントが市場をリードし、2024年から2030年にかけて最も速いCAGRを記録すると予測されます。これは、新規バイオマーカーキットの開発に向けて大手企業が広範な研究開発イニシアチブを取っているためです。
• イムノアッセイセグメントは、新規免疫診断ソリューションの開発に関する研究開発の高まりにより、2023年に市場をリードしました。
• 分子診断セグメントは、先進的で革新的な分子診断機器の開発により、2024年から2030年にかけて最も速いCAGRで成長すると予測されています。
• 病院の最終用途セグメントは、質の高い医療を提供する主要な医療機関が革新的な機器を病院に提供するという一般的な動向により、2023年に市場をリードしました。
• 北米は、高度な医療インフラ、対象疾患の有病率の上昇、良好な規制環境などの要因により、2023年の世界市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 心臓病・神経向けIVD市場：変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 心臓病・神経向けIVD市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • 体積分析（機器）

第4章 心臓病・神経向けIVD市場：製品タイプの推定・動向分析

• 心臓病・神経向けIVDの世界市場：製品タイプのダッシュボード
• 心臓病・神経向けIVDの世界市場：製品タイプの変動分析
• 心臓病・神経向けIVDの世界市場、製品タイプ別、収益
• 機器
• 試薬・消耗品
• ソフトウェア・サービス

第5章 心臓病・神経向けIVD市場：技術の推定・動向分析

• 心臓病・神経向けIVDの世界市場：技術のダッシュボード
• 心臓病・神経向けIVDの世界市場：技術の変動分析
• 心臓病・神経向けIVDの世界市場、技術別、収益
• イムノアッセイ
• 分子診断
• 血液
• その他

第6章 心臓病・神経向けIVD市場： 最終用途の推定・動向分析

• 心臓病・神経向けIVDの世界市場：最終用途のダッシュボード
• 心臓病・神経向けIVDの世界市場：最終用途の変動分析
• 心臓病・神経向けIVDの世界市場、最終用途別、収益
• 病院
• 臨床検査室
• その他

第7章 心臓病・神経向けIVD市場：地域の推定・動向分析、製品タイプ別、技術別、最終用途別

• 地域のダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • Siemens Healthineers AG
  • Quest Diagnostics Incorporated
  • Abbott
  • BD（Becton Dickinson）
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
• Table 3 North America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 4 North America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 6 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 7 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 8 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 10 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 11 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 14 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 15 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 16 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 17 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 18 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 19 UK in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 20 UK in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 21 UK in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 22 France in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 23 France in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 24 France in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 26 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 27 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 29 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 30 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 32 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 33 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 34 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 35 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 36 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 38 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 39 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 43 Aisa Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 44 China in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 45 China in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 46 China in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 47 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 48 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 49 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 50 India in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 51 India in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 52 India in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 53 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 54 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 55 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 56 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 57 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 58 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 60 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 61 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
• Table 63 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 64 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 65 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 66 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 67 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 68 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 69 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 70 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 71 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 72 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 73 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 74 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 75 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 77 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 78 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 79 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 80 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 81 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 85 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 86 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 87 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
• Table 88 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
• Table 89 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
• Table 90 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 In vitro diagnostics (IVD) in cardiology and neurology market: market outlook
• Fig. 14 In vitro diagnostics (IVD) in cardiology and neurology competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 In vitro diagnostics (IVD) in cardiology and neurology market driver impact
• Fig. 18 In vitro diagnostics (IVD) in cardiology and neurology market restraint impact
• Fig. 19 In vitro diagnostics (IVD) in cardiology and neurology market: Product type movement analysis
• Fig. 20 In vitro diagnostics (IVD) in cardiology and neurology market: Product type outlook and key takeaways
• Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Reagents & consumables estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Software and services market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 In vitro diagnostics (IVD) in cardiology and neurology market: Technology movement analysis
• Fig. 25 In vitro diagnostics (IVD) in cardiology and neurology market: Technology outlook and key takeaways
• Fig. 26 Immunoassays market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Molecular diagnostics estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 In vitro diagnostics (IVD) in cardiology and neurology market: End-use movement analysis
• Fig. 31 In vitro diagnostics (IVD) in cardiology and neurology market: End-use outlook and key takeaways
• Fig. 32 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Clinical laboratories estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional movement analysis
• Fig. 36 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional outlook and key takeaways
• Fig. 37 Global in vitro diagnostics (IVD) in cardiology and neurology market share and leading players
• Fig. 38 North America, by country
• Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 U.S. key country dynamics
• Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Canada key country dynamics
• Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 UK key country dynamics
• Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Germany key country dynamics
• Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 France key country dynamics
• Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Italy key country dynamics
• Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Spain key country dynamics
• Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Denmark key country dynamics
• Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Sweden key country dynamics
• Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Norway key country dynamics
• Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 China key country dynamics
• Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Japan key country dynamics
• Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 India key country dynamics
• Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Thailand key country dynamics
• Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 South Korea key country dynamics
• Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Australia key country dynamics
• Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Brazil key country dynamics
• Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Mexico key country dynamics
• Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Argentina key country dynamics
• Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 South Africa key country dynamics
• Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Saudi Arabia key country dynamics
• Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 UAE key country dynamics
• Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Kuwait key country dynamics
• Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Market share of key market players- In vitro diagnostics (IVD) in cardiology and neurology market

IVD In Cardiology And Neurology Market Growth & Trends:

The global IVD in cardiology and neurology market size is anticipated to reach USD 30.54 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of cardiovascular and neurological disorders aided by the growing geriatric population. According to an article published by the World Heart Federation, in 2023, cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated deaths registered being 20.5 million in 2021. Moreover, neurological disorders are found to affect 15% of the total population globally.

Innovative treatments that combine new or existing medicines with biomarkers are continuously being launched. For instance, currently, biomarkers are used for the treatment of neurological diseases to track brain health by measuring molecules. Recent progressions in biomarkers, such as biomarker signatures, are enhancing the treatment of neurological diseases. This has resulted in early diagnosis, faster drug development, and noninvasive testing. Moreover, digital biomarkers offer numerous pharmaceutical companies contextual and supplemental information to conclude clinical trial decisions. For instance, IXICO Plc is collaborating with major biopharmaceutical firms to authenticate clinically digital biomarkers and use them in clinical trials.

Moreover, the development and introduction of BBBM tests for the diagnosis of indications, such as AD & mild traumatic brain injury, among others, are contributing to market growth. For instance, in March 2020, NIH-funded researchers developed a blood-based test for detecting phosphorylated-tau-181 (ptau181), indicating Alzheimer's disease presence. This approach is less costly and invasive than the existing brain imaging & spinal fluid tests. Similarly, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Furthermore, IVDs are gaining increasing importance across various clinical fields for the diagnosis and monitoring of various diseases. A rise in the availability of novel IVD solutions for cardiovascular and neurological disorders is one of the major drivers anticipated to boost market growth. For instance, in October 2023, Mindray announced the expansion of its cardiac biomarker portfolio with the launch of two novel highly sensitive NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers. With this launch, the company aims to enhance and diversify its existing portfolio with innovative technologies for better diagnosis and management of CVDs. Moreover, in July 2023, Quest Diagnostics announced the availability of the first test available for consumers, the AD-Detect Test for Alzheimer's Disease that helps in accessing the potential risk of developing Alzheimer's disease.

IVD In Cardiology And Neurology Market Report Highlights:

• The reagents & consumables segment led the market and is anticipated to register the fastest CAGR from 2024 to 2030 owing to extensive R&D initiatives being undertaken by major players for the development of novel biomarker kits
• The immunoassays segment led the market in 2023 due to the rising R&D about the development of novel immunological diagnostic solutions
• The molecular diagnostic segment is anticipated to grow at the fastest CAGR from 2024 to 2030 owing to the development of advanced and innovative molecular diagnostics instruments
• The hospitals end-use segment led the market in 2023 due to the popular trend of providing innovative devices in hospitals by key plato provideiding quality care
• North America dominated the global market in 2023 owing to factors, such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Technology
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type and technology outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases such as cardiovascular and neurological disorders
    • 3.2.1.2. Technological advancement
    • 3.2.1.3. Increasing demand for point-of-care diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of devices
    • 3.2.2.2. Stringent regulatory policies
• 3.3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Volume Analysis (Instruments)

Chapter 4. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Estimates & Trend Analysis

• 4.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Dashboard
• 4.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Movement Analysis
• 4.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Product Type, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Software and Services
  • 4.6.1. Software and services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Estimates & Trend Analysis

• 5.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Dashboard
• 5.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Movement Analysis
• 5.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Technology, Revenue
• 5.4. Immunoassays
  • 5.4.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Molecular Diagnostics
  • 5.5.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Hematology
  • 5.6.1. Hematology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Estimates & Trend Analysis

• 6.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Dashboard
• 6.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Movement Analysis
• 6.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by End-use, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Laboratories
  • 6.5.1. Clinical laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Thermo Fisher Scientific Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. F. Hoffmann-La Roche Ltd
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sysmex Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Siemens Healthineers AG
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Quest Diagnostics Incorporated
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Abbott
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. BD (Becton Dickinson)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Bio-Rad Laboratories, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Beckman Coulter, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives